评估存在血管疾病或糖尿病的老年人血管事件预防与认知功能:3项随机临床试验的二次分析
该研究为3项随机临床试验(HPS、SEARCH、HPS2-THRIVE)的二次分析,纳入45 029例完成认知评估的幸存者(平均年龄67.9岁,80.7%为男性),平均随访4.9年,使用14项词语测试评估认知功能。结果显示,发生卒中(n=1197)与7.1年(95%CI 5.7-8.5)的认知老化相关;短暂性脑缺血发作、心肌梗死、心力衰竭和新发糖尿病与1至2年认知老化相关。在HPS中,随机接受他汀治疗5年使2.0%的幸存者避免非致死性卒中或短暂性脑缺血发作,2.4%避免非致死性心脏事件,预期认知老化减少0.15年(95%CI 0.11-0.19)。HPS对1年认知老化差异(即5年内20%)的检出把握度为80%。作者认为,预防治疗对心血管事件的认知获益在即使最大的随机临床试验中也可能太小而无法检测,因此阴性结果不能充分证明长期使用无益。
要点
- 卒中与7.1年(95%CI 5.7-8.5)的认知老化相关,是认知损害的主要血管事件。
- 短暂性脑缺血发作、心肌梗死、心力衰竭和新发糖尿病分别与1至2年认知老化相关。
- HPS中他汀治疗5年使2.0%幸存者避免非致死性卒中或短暂性脑缺血发作,2.4%避免非致死性心脏事件,预期认知老化减少0.15年(95%CI 0.11-0.19)。
- HPS对1年认知老化差异(5年内20%)的检出把握度为80%,提示试验可能无法检出有意义的认知获益。
- 作者认为,无统计学显著性的结果不能提供良好证据表明长期预防治疗对认知功能无 worthwhile 获益。
适用人群与场景
- 纳入:3项随机临床试验(HPS、SEARCH、HPS2-THRIVE)中完成最终试验内随访且接受认知评估的幸存者,均存在闭塞性血管疾病或糖尿病。
- 排除:未完成认知评估或未存活至最终随访者。
研究设计与关键结果
- 研究类型:3项随机临床试验(HPS、SEARCH、HPS2-THRIVE)的二次分析;样本量:45 029例完成认知评估;人群:存在闭塞性血管疾病或糖尿病,平均年龄67.9岁(SD 8.0),80.7%为男性;干预与对照:他汀类药物调脂治疗 vs 对照;主要终点:最终试验内随访时认知功能(14项词语测试),平均随访4.9年(SD 1.5)。
- 发生卒中(n=1197)与7.1年(95%CI 5.7-8.5)的认知老化相关。
- 新发短暂性脑缺血发作、心肌梗死、心力衰竭和新发糖尿病分别与1至2年的认知老化相关。
- 在HPS中,随机接受他汀治疗5年使2.0%的幸存者避免非致死性卒中或短暂性脑缺血发作,2.4%避免非致死性心脏事件,预期认知老化减少0.15年(95%CI 0.11-0.19)。
- HPS中15 926例完成认知评估,对1年(即5年内20%)认知老化差异的检出把握度为80%。
证据类型、等级与局限
- 证据类型:3项随机临床试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,预防治疗对心血管事件的认知获益在即使最大的随机临床试验中也可能太小而无法检测;因此,无统计学显著性的结果可能不能提供良好证据表明长期使用此类治疗对认知功能无 worthwhile 获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Acquisition of reliable randomized clinical trial evidence of the effects of cardiovascular interventions on cognitive decline is a priority.
OBJECTIVES: To estimate the association of cognitive aging with the avoidance of vascular events in cardiovascular intervention trials and understand whether reports of nonsignificant results exclude worthwhile benefit.
DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of 3 randomized clinical trials in participants with preexisting occlusive vascular disease or diabetes included survivors to final in-trial follow-up in the Heart Protection Study (HPS), Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH), and Treatment of HDL (High-Density Lipoprotein) to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials of lipid modification for prevention of cardiovascular events. Data were collected from February 1994 through January 2013 and analyzed from January 2015 through December 2018.
EXPOSURES: Incident vascular events and diabetes and statin therapy.
MAIN OUTCOMES AND MEASURES: Cognitive function was assessed at the end of a mean (SD) of 4.9 (1.5) years of follow-up using a 14-item verbal test. Associations of the incidence of vascular events and new-onset diabetes during the trials, with cognitive function at final in-trial follow-up were estimated and expressed as years of cognitive aging (using the association of the score with age >60 years). The benefit on cognitive aging mediated through the effects of lowering low-density lipoprotein cholesterol levels on events was estimated by applying these findings to nonfatal event differences observed with statin therapy in the HPS trial.
RESULTS: Among 45 029 participants undergoing cognitive assessment, mean (SD) age was 67.9 (8.0) years; 80.7% were men. Incident stroke (n = 1197) was associated with 7.1 (95% CI, 5.7-8.5) years of cognitive aging; incident transient ischemic attack, myocardial infarction, heart failure, and new-onset diabetes were associated with 1 to 2 years of cognitive aging. In HPS, randomization to statin therapy for 5 years resulted in 2.0% of survivors avoiding a nonfatal stroke or transient ischemic attack and 2.4% avoiding a nonfatal cardiac event, which yielded an expected reduction in cognitive aging of 0.15 (95% CI, 0.11-0.19) years. With 15 926 participants undergoing cognitive assessment, HPS had 80% power to detect a 1-year (ie, 20% during the 5 years) difference in cognitive aging.
CONCLUSIONS AND RELEVANCE: The expected cognitive benefits of the effects of preventive therapies on cardiovascular events during even the largest randomized clinical trials may have been too small to be detectable. Hence, nonsignificant findings may not provide good evidence of a lack of worthwhile benefit on cognitive function with prolonged use of such therapies.
TRIAL REGISTRATION: isrctn.com and ClinicalTrials.gov Identifiers: ISRCTN48489393, ISRCTN74348595, and NCT00461630.
参考来源
- Offer A, Arnold M, Clarke R, et al. Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA Netw Open. 2019. PMID: 30821829. doi:10.1001/jamanetworkopen.2019.0223
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。